Why Shire PLC And AstraZeneca plc Are Falling Today

Investors in Shire PLC (LON:SHP) and AstraZeneca plc (LON:AZN) are selling in response to new US tax rules.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaShares in Shire (LSE: SHP) (NASDAQ: SHPG.US) and AstraZeneca (LSE: AZN) (NYSE: AZN.US) fell by more than 5% when markets opened this morning.

These sell-offs were triggered by overnight news that the US government is clamping down on so-called tax inversion deals, by which US companies reduce their tax rate by taking over foreign companies.

The news appears to threaten the success of Shire’s takeover deal with US pharma firm AbbVie and makes a repeat bid for AstraZeneca from Pfizer seem more unlikely.

What’s changed?

The US Treasury Department has announced new rules, which apply from today, making it harder for US firms to move their tax bases abroad.

The rules are fairly technical, but are intended to restrict the ability of American companies to move cash and profits abroad without paying US taxes.

Will the Shire deal still happen?

Shire’s share price fell by nearly 6% to just over £49 this morning, signalling investors’ concern that the AbbVie takeover might not go through. Neither company has commented on the new rules yet, so we don’t know if AbbVie is planning to reconsider its offer.

However, today’s fall in Shire’s share price means that the firm’s current market value is almost 10% below the agreed deal valuation, suggesting that the market sees a real risk the AbbVie deal could fail.

Will Pfizer abandon AstraZeneca?

Pfizer’s chief executive Ian Read was open about the fact that tax inversion was an important element of his company’s desire to takeover AstraZeneca.

AstraZeneca’s share price has remained high despite the failure of the Pfizer bid, partly because investors have been hoping that Pfizer will try again later this year.

In my view, the new rules on tax inversion deals make a repeat bid from Pfizer less likely, but not impossible: companies such as Pfizer may look at the new rules in detail and calculate their precise impact, before making a final decision.

Is either company a buy?

After today’s falls, AstraZeneca shares are about 10% higher than they were before the Pfizer bid, giving the firm a 2015 forecast P/E of around 17.5, with a prospective yield of around 3.9%.

Shire looks more expensive: with a 2015 forecast P/E of 23 and a prospective yield of just 0.4%, I can see no reason for buying, except as a gamble that the AbbVie bid will go through at its original valuation.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland does not own shares in any company mentioned.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »